Advaxis Incorporated (ADXS)

Oncology Corporate Profile

Stock Performance

8.0600
-0.6300

HQ Location

305 College Road East
Princeton, NJ 8902

Company Description

Advaxis, Inc. is a biotechnology company that uses a modified infectious microorganism to activate the immune system to treat cancer, infectious disease or allergic syndromes. Based upon over a 10 years of innovative work done by Yvonne Paterson, Ph.D., Professor of Microbiology at the University of Pennsylvania, it has been found that the unique microbe Listeria monocytogenes is capable of stimulating numerous aspects of the immune system simultaneously; coordinating innate, humoral (antibody), and cellular adaptive immune responses in an extremely effective response to existing cancers and other diseases.

Website: http://www.advaxis.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ADXS-HPVimmunotherapyCervical Intraepithelial NeoplasiaII
ADXS-HPVimmunotherapyHead & Neck cancerII
ADXS31-142 (+ pembrolizumab)Lm-LLO immunotherapyProstate cancerIMerck
ADXS31-164immunotherapyBreast cancerPreclinical
ADXS31-142immunotherapyProstate cancerPreclinical

View additional information on product candidates here »

Source


http://www.advaxis.com

Recent News Headlines

Advaxis Announces GOG-0265 12-month Overall Survival Rate of 37.5% in Stage 2

10/24/2016 11:52 am

(Advaxis) Oct 24, 2016 - Advaxis, Inc., a clinical stage biotechnology company developing cancer immunotherapies, today announced topline results from the early closure of stage 2 of the Phase 2 GOG-0265 trial, conducted by the Gynecologic Oncology Group (GOG, now part of NRG Oncology) and supported by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI).

Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage

8/11/2016 11:36 am

(Yahoo! Finance) Aug 11, 2016 - Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced that its Phase 2 “window of opportunity” clinical study of its lead immunotherapy candidate, axalimogene filolisbac (AXAL), in patients with late-stage HPV-associated oropharyngeal cancer (HPVOPC) met its stage 1 primary objective and is advancing into the second stage of the clinical study.

Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration

8/2/2016 08:41 am

(Amgen) Aug 2, 2016 - Amgen and Advaxis, Inc. today announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor.

Advaxis’ AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients

7/21/2016 10:49 am

(Yahoo! Finance) July 21, 2016 - Advaxis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the Company’s lead immunotherapy candidate, axalimogene filolisbac (AXAL), as a Fast Track product for adjuvant therapy for high-risk locally advanced cervical cancer patients.

FDA Grants Special Protocol Assessment to Advaxis’ Phase 3 Study of AXAL in Patients with Cervical Cancer

7/6/2016 12:13 pm

(P&T Community) July 6, 2016 - Advaxis, Inc., a clinical stage biotechnology company developing cancer immunotherapies, today announced that it reached an agreement with the U.S. Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, for the Phase 3 AIM2CERV trial evaluating the Company’s lead Lm immunotherapy candidate, axalimogene filolisbac (AXAL), in patients with high-risk, locally advanced cervical cancer (HRLACC).

Adjuvant Chemotherapy Improves Overall Survival in Patients with Stage IB Non-Small Cell Lung Cancer

6/14/2016 07:02 am

(IASLC) June 13, 2016 - The use of adjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC) patients improves overall survival (OS) and 5-year OS in patients with tumor sizes ranging from 3 - 7 cm.

Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer

6/8/2016 11:41 am

(TheStreet) June 8, 2016 - Advaxis, Inc., a clinical stage biotechnology company developing cancer immunotherapies, today announced dose administration for the first patient in the first stage of its Phase 2 clinical trial of their FAWCETT study, testing the Company’s lead immunotherapy candidate, axalimogene filolisbac (AXAL), in patients with persistent or recurrent metastatic anal cancer.

FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma

4/28/2016 12:03 pm

(Advaxis) Apr 28, 2016 - Advaxis, Inc., a clinical stage biotechnology company developing cancer immunotherapies, today announced that the Food and Drug Administration (FDA) has granted Fast Track Designation for the company's immunotherapy product candidate ADXS-HER2 for patients with newly-diagnosed, non-metastatic, surgically-resectable osteosarcoma.

Colorectal Cancer Screening: Not All It's Cracked Up to Be?

4/28/2016 11:05 am

(Medscape Medical News) Apr 27, 2016 - "Unambiguous good news" — that's what the trends are in colorectal cancer incidence and mortality for adults 50 years and older in the United States, according to a pair of experts.

FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma

4/28/2016 06:50 am

(Advaxis) Apr 28, 2016 - Advaxis, Inc., a clinical stage biotechnology company developing cancer immunotherapies, today announced that the Food and Drug Administration (FDA) has granted Fast Track Designation for the company’s immunotherapy product candidate ADXS-HER2 for patients with newly-diagnosed, non-metastatic, surgically-resectable osteosarcoma.

VolitionRx Announces Study Results Showing NuQ® Blood Test Detects Prostate Cancer Early with Significantly Higher Accuracy than PSA Test

4/20/2016 12:01 pm

(Yahoo! Finance) Apr 20, 2016 - VolitionRx Limited today announced that a single NuQ® biomarker assay detected 71% of early stage I prostate cancer cases at 93% specificity.

Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL Highlights Potential of the Company’s Lm Technology™ Platform

4/18/2016 11:19 am

(Advaxis) Apr 18, 2016 - First clinical data with AXAL to show evidence of cytotoxic T cell infiltration into the tumor immune microenvironment or TME for HPV-Positive oropharyngeal cancer.

ELCC 2016 News: Comprehensive Molecular Profiling Shows Disparity Between Primary NSCLC Tumours and Metastases

4/15/2016 11:00 am

(ESMO) Apr 15, 2016 - Important differences of up to 47% in the expression rates of biomarkers between the primary tumour and metastatic sites were detected using comprehensive molecular profiling of non-small-cell lung cancer (NSCLC) samples.

Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts

4/5/2016 11:14 am

(Yahoo! Finance) Apr 5, 2016 - Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, and Merck & Co., Inc., today announced that they have completed the first two dose-escalation cohorts and launched the third dose-escalation cohort in their KEYNOTE-046 clinical trial.

New Law Allows Donation Of Unused Cancer Drugs

4/5/2016 11:02 am

(WLBZ-TV [NBC], Ch. 2 [Bangor, ME]/KING) Apr 5, 1016 - A new law will allow cancer patients in Washington state to donate their unused cancer drugs that have not been tampered with to people in need who may be underinsured or uninsured.

J&J Psoriasis Drug Stelara Eases Crohn's Disease in Second Trial

3/18/2016 10:02 am

(Reuters) Mar 18, 2016 - Johnson & Johnson's Stelara psoriasis drug has shown effectiveness against Crohn's disease in a second late-stage trial, the company said on Friday, bolstering prospects of its approval for the additional use.

CAR Trials Drive Leukemia and Lymphoma Treatment in New Direction

2/24/2016 11:05 am

(UC San Diego Health) Feb 23, 2016 - Researchers at UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells – one of the immune system’s primary weapons – to treat three different types of blood cancer that often defy existing therapies.

Canadian Experts Say 'No' To Colonoscopy For Colon Cancer Screening

2/23/2016 11:05 am

(Reuters Health) Feb 22, 2016 - The Canadian Task Force on Preventive Health care recommends that colonoscopy should not be used to screen adults for colon cancer. Instead, they suggest testing for microscopic amounts of blood in the stool.

FDA Lifts Clinical Hold On Advaxis' Cancer Compounds

12/16/2015 11:37 am

(Reuters) Dec 16, 2015 - Drug developer Advaxis Inc said on Wednesday the U.S. Food and Drug Administration had lifted a clinical hold on three of its experimental cancer therapies, sending the company's shares up as much as 38 percent.

Advaxis Provides Additional Information on Clinical Hold

11/3/2015 06:44 am

(StreetInsider) Nov 2, 2015 - Advaxis, Inc. today provided additional information about the clinical hold issued by the U.S. Food and Drug Administration (FDA) on the Company’s Investigational New Drug (IND) application for axalimogene filolisbac.

FDA Expands Use of Bristol Myers' Cancer Drug Yervoy

10/29/2015 11:05 am

(Reuters) Oct 28, 2015 - The U.S. Food and Drug Administration expanded the use of Bristol-Myers Squibb Co's skin cancer drug, Yervoy, as an additional therapy for patients with late-stage melanoma.

UnitedHealthcare Expands Effort to Rein in Rising Costs of Cancer Treatment

10/29/2015 11:05 am

(KHN) Oct 29, 2015 - UnitedHealthcare said Thursday it will expand its high-profile test of whether bundled payments for chemotherapy can help slow rising cancer treatment costs, part of a growing effort by insurers to find new ways to pay for care.

Coming: Prostate Cancer Treatment Guided by Biomarkers

10/29/2015 11:05 am

(Medscape Medical News) Oct 28, 2015 - In a phase 2 study, men with metastatic castration-resistant prostate cancer whose tumors harbored certain DNA-repair defects were much more likely to respond to the oral PARP (poly [ADP-ribose] polymerase) inhibitor olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) than their peers whose tumors did not have these mutations.

A Grim Breast Cancer Milestone for Black Women

10/29/2015 11:05 am

(New York Times/Well blog) Oct 29, 2015 - For the first time, the incidence of breast cancer among black women is equal to that of white women, according to a sweeping new report from the American Cancer Society.

MEK Inhibitor Falls Flat in Pretreated Multiple Myeloma

10/29/2015 11:05 am

(MedPage Today) Oct 28, 2015 - The MEK inhibitor selumetinib (AZD6244) proved tolerable, but only minimally active as a single agent in heavily pretreated patients with relapsed or refractory multiple myeloma, according to findings from a six-center nonrandomized phase II trial.

Retroviral RNA May Play a Part in Liver Cancer

10/29/2015 11:05 am

(RIKEN [Japan]) Oct 29, 2015 - An international group led by RIKEN in Japan and INSERM in France have found that retroviral long-terminal-repeat (LTR) promoters—a type of repetitive element that are widely distributed in the human genome—are highly activated in hepatocellular carcinomas, the most common type of liver cancer.

Landmark Clinical Trial Shows Gene-Targeted Drug Can Treat Prostate Cancer

10/29/2015 06:03 am

(ICR [UK]) Oct 28, 2015 - A pioneering drug developed to treat women with inherited cancers can also benefit men with advanced prostate cancer, a major new clinical trial concludes.

Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for Yervoy (ipilimumab) as Adjuvant Treatment for Fully Resected Stage III Melanoma

10/29/2015 06:03 am

(MarketWatch) Oct 28, 2015 - First company to demonstrate the potential of an immune checkpoint inhibitor in the adjuvant treatment for these patients.

FDA Approves Yervoy To Reduce The Risk Of Melanoma Returning After Surgery

10/28/2015 04:03 pm

(FDA.gov) Oct 28, 2015 - Today the U.S. Food and Drug Administration expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery.

Astellas Inititaties Phase 3 Registration Trial of gilteritinib (ASP2215) in Relapsed or Refractory Acute Myeloid Leukemia Patients

10/28/2015 12:02 pm

(Astellas) Oct 28, 2015 - Astellas Pharma Inc. today announced dosing of the first patient in a randomized Phase 3 registration trial of gilteritinib (ASP2215) versus salvage chemotherapy in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The primary endpoint of the trial is overall survival (OS).

FDA Issues Complaints Against Bloodwork Biotech Firm Theranos

10/28/2015 12:00 pm

(USA Today) Oct 28, 2015 - Pressure on Silicon Valley biotech startup Theranos increased Tuesday with the Food and Drug Administration's release of complaints against the bloodwork company based on facility inspections earlier this summer.

Death From Heart Disease, Cancer And Other Big Causes Less Premature

10/28/2015 12:00 pm

(CNN) Oct 27, 2015 - The researchers found that the overall death rate has dropped sharply (42.9%) over the last four decades.

Medicare Cut for Physicians Helps Balance New Budget Deal

10/28/2015 12:00 pm

(Medscape Medical News) Oct 28, 2015 - To help offset an $80 billion spending increase, the bipartisan bill would extend a 2% sequestration cut of Medicare payment rates into fiscal 2025.

E-Cigarettes Appeal to Smokers Who Are Trying to Quit, Study Says

10/28/2015 12:00 pm

(Wall Street Journal) Oct 28, 2015 - A federal study on U.S. e-cigarette use among adults shows the devices appeal to current and former smokers trying to kick their cigarette habit.

What’s Got Americans Worried? Drug Costs

10/28/2015 11:05 am

(KHN Morning Briefing) Oct 28, 2015 - A new poll says the public's top health care concern is how much prescription drugs will cost them. Most Americans also believe the FDA should review drug ads before they air.

Advaxis Launches MINE(TM) Collaboration

10/27/2015 11:18 am

(CNN Money) Oct 27, 2015 - Advaxis, Inc. today announced the launch of a research collaboration with Memorial Sloan Kettering Cancer Center (MSK), a premier cancer center committed to patient care and innovative research, to evaluate the immunologic and anti-tumor activity of patient tumor-specific, neoepitope-based immunotherapy.

FDA Puts Clinical Hold On Advaxis Cancer Drug

10/7/2015 11:32 am

(Reuters) Oct 6, 2015 - Advaxis Inc said the U.S. Food and Drug Administration has put on hold the mid-stage trials of its experimental cancer drug after a patient died, sending its shares down 27 percent in extended trading.

Advaxis Cancer Immunotherapy on Hold Due to Patient Death

10/7/2015 07:14 am

(TheStreet) Oct 6, 2015 - The U.S. Food and Drug Administration placed a halt on clinical trials involving a cancer immunotherapy from Advaxis because of concerns a bacteria used to deliver the drug may have contributed to a patient death.

First Human Patient Treated in Phase 1b Study of Advaxis's ADXS-HER2 in HER2 Expressing Solid Tumors

9/28/2015 02:03 pm

(Yahoo! Finance) Sept 28, 2015 - Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, announced that the first patient was treated in a Phase 1b dose-escalation clinical study of ADXS-HER2 for the treatment of patients with metastatic HER2 expressing solid tumors.

Advaxis Therapy Improves Survival Rates in Cervical Cancer Patients

9/18/2015 11:27 am

(Reuters) Sept 17, 2015 - Advaxis Inc said its experimental cancer vaccine was found more effective in improving survival rates of cervical cancer patients than standard therapy, validating the technology behind its pipeline of cancer treatments.

Advaxis's Axalimogene Filolisbac (ADXS-HPV) Showed 38.5 Percent 12-Month Survival in Patients With Persistent/Recurrent Metastatic Cervical Cancer

9/18/2015 07:17 am

(CNNMoney) Sept 17, 2015 - Advaxis, Inc. and the Gynecologic Oncology Group (GOG, now part of NRG Oncology), today announced clinical data from Stage 1 of an ongoing two-stage Phase 2 study (GOG-0265) of Advaxis's lead Lm Technology(TM) immunotherapy, axalimogene filolisbac (ADXS-HPV), in patients with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC) who have progressed on at least one prior line of systemic therapy.

Phase 2 Study of Advaxis's Axalimogene Filolisbac (ADXS-HPV) in Cervical Cancer to be Presented at 2015 AGOS Annual Meeting

8/31/2015 10:57 am

(CNNMoney) Aug 31, 2015 - Advaxis, Inc. today announced that final clinical data from Stage 1 of the ongoing two-stage Phase 2 study (GOG-0265) of Advaxis's lead Lm Technology™ immunotherapy, axalimogene filolisbac (ADXS-HPV), in patients with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC), will be presented at the American Gynecological & Obstetrical Society (AGOS) annual meeting.

Advaxis and MedImmune Commence Enrollment in Phase I/II Study of Axalimogene Filolisbac (ADXS-HPV) in Combination with Durvalumab (MEDI4736) for the Treatment of HPV-Associated Cancers

8/20/2015 12:19 pm

(Yahoo! Finance) Aug 20, 2015 - Advaxis, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, today announced that enrollment has commenced in a Phase I/II clinical trial of axalimogene filolisbac (ADXS-HPV), Advaxis's investigational Lm Technology™ immunotherapy.

Increased Radiation Dose Offers No Survival Benefit for Patients with Low-Risk Prostate Cancer, Penn Study Finds

7/16/2015 11:03 am

(Penn Medicine) July 16, 2015 - Increased radiation dose is associated with higher survival rates in men with medium- and high-risk prostate cancer, but not men with low-risk prostate cancer, according to a new study from Penn Medicine published this week in JAMA Oncology.

Advaxis Submits Special Protocol Assessment Request to FDA for ADXS-HPV Phase 3 Clinical Trial in Cervical Cancer

6/15/2015 12:23 pm

(MarketWatch) June 15, 2015 - Advaxis, Inc. today announced the company has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA) to initiate detailed design discussions for a Phase 3 clinical study of ADXS-HPV for the treatment of high-risk, locally advanced cervical cancer (HRLACC).

Viewpoint: Refining Lung Cancer Staging in the Molecular Oncology Era

5/20/2015 11:05 am

(Medscape Oncology) May 19, 2015 - Dr. Jack West comments on a very provocative proof of principle demonstrating the effect next-generation sequencing may have on tumor staging.